Loading...
•
Mar 31, 2020
Akero Q1 2020 Earnings Report
Akero Therapeutics reported first quarter financial results, highlighting progress in advancing AKR-001 and the ongoing Phase 2a clinical trial.
Key Takeaways
Akero Therapeutics reported its first quarter financial results, emphasizing the progress of AKR-001 as a potential treatment for NASH. The company highlighted the significant reductions in liver fat and ALT observed in the BALANCED study and is on track to initiate a Phase 2b clinical trial in the first half of 2021.
Reported results for the primary endpoint and several secondary efficacy endpoints in the Phase 2a BALANCED study.
Continued to advance AKR-001 as a potential cornerstone treatment for NASH.
Observed significant reductions in liver fat and ALT with AKR-001, among the largest reported for NASH clinical studies.
Remained on schedule to initiate Phase 2b clinical trial in NASH patients in the first half of 2021.
Forward Guidance
Akero Therapeutics is on track to initiate its Phase 2b clinical trial in NASH patients in the first half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...